

# Engaging Men in HIV testing: What works?

**Experience from HPTN071** 

Helen Ayles
Zambart, Zambia
October 2017



### Why focus on men?

- "Men are being left behind in the push to 90-90-90, in turn affecting the lives of women and children" UNAIDS report 2017
- Why do we only talk about men in relation to preventing infections in women?
- Are men a "key population"?
  - Key to the epidemic
  - Key to the response











#### TREATMENT COVERAGE LOWER AMONG MEN




Figure 3.17. Antiretroviral therapy coverage among adults living with HIV aged 15 years and older, by sex, by region, 2016


Source: Global AIDS Monitoring, 2017. UNAIDS 2017 estimates.






#### What are the barriers for men?

- Men often portrayed negatively in HIV discourse
  - Bringing the virus into relationships
  - Infecting young women
  - Perpetrating GBV
- HIV services are less accessible for men
- HIV may threaten masculinity "real men don't get sick"
- "Men usually say that HIV testing is for women" DiCarlo et al Culture Health and Sexuality 2014





#### **HIV Care and Prevention Continua**






#### The Case of Zambia -ZAMPHIA

#### Overall men:

- Less likely to know their status
- As likely to get onto ART
- Less likely to be virally suppressed





### Why are we missing the men?



Findings from Zambia after one year of the PopART universal testing and treatment intervention





Fig 2. Cascade of care from enumeration of household members through ART initiation during the first annual round of the PopART intervention. ART, antiretroviral therapy.



#### When we find men they test.....



- Known status before: self-reported HIV-positive or tested HIV-negative elsewhere in the previous 12 months
- Known status after: self-reported HIV-postive, tested by the CHiPs or tested HIV-negative elsewhere in the previous 12 months



## ....and when they test they do link to services



Findings from Zambia after one year of the PopART universal testing and treatment intervention




Fig 3. Time from referral to linkage to care and ART initiation during the first annual round of the PopART intervention. Survival curves showing cumulative proportions linking to care or initiating ART following referral by community HIV-care providers. ART, antiretroviral therapy.



### How do we engage the men?

- Male Spaces
  - VMMC uniquely male preserve
  - Male campaigns
  - Male clinics
- New initiatives


HIV-ST "HIV-self testing is for the men....."

- Painless/bloodless
- Secondary distribution by women at ANC/FSW/community





### "Man Up"





- Provided a range of health services
- Football matches, performances
- Raffle



#### What worked.....what didn't?

- Lots of people came
- Accessed many health services
- Registration of people into their households very challenging and time consuming
- Costly
- Few additional men and households.....but is value in numbers or in reaching the "last 20%"





#### Local Initiatives

- Local campaigns for VCT day etc
- Following men to work
- Meeting men at bars







### Is HIV self-testing a solution?


- Previous studies have found that certain groups seem to be reached more with HIV self-testing
  - Men
  - Youth
  - Key populations
- Secondary distribution using women to reach men has been successfully used
  - Mostly ANC and from HIV-ve women
- Could self testing help us?






### **HPTN071 (PopART) Trial**

HPTN071 (PopART) is a cluster randomised trial being conducted in 21 urban communities in Zambia and South Africa (population ~ 1m) to investigate whether a combination HIV prevention package including Universal HIV testing and treatment can reduce HIV incidence at community level





Universal treatment for HIV +ve irrespective of CD4 count

CHiPs: Community HIV-care Providers PMTCT: Prevention of Mother to Child

Transmission

VMMC: Voluntary Medical Male Circumcision

TB: Tuberculosis


STI: Sexually Transmitted Infections






### **Ancillary Background**

- HPTN071 has been very successful in attaining the first 90 in urban mobile populations
- However testing gaps remain
  - Men
  - Young adults
  - Most mobile individuals
- To address these gaps we piloted offering oral HIV selftesting (HIV-ST) in addition to standard HIV testing services (HTS)









### **Design and Outcome**


- Two-arm cluster randomised trial, with unit of randomisation being zones within a community covered by a pair of lay counsellors (CHiPs)
- Primary outcome was the proportion of resident adolescents and adults (aged 16 years and older) who know their HIV status.
  - We define knowledge of HIV status as an individual selfreporting knowing their HIV-positive status or accepting an offer of HTS from the lay counsellor.
- Predefined subgroup analyses
  - Sex
  - Age group (16-29 Vs 30+)





#### **Methods**

- Four of the HPTN071 (PopART) intervention communities in Zambia were included in this pilot
- These four communities had a total of 66 Community HIV Provider (CHiP) zones
- Zones were randomly allocated to continue with the standard PopART intervention or to offer a choice of HTS including oral HIVST





referral for

- VMMC

- STI

- Tuberculosis



#### Standard of care arm

#### Universal testing: annual door-**Facilitated** to-door HBT Service promotion and Follow-up - HIV care for HIV +ve Support for: on referral including PMTCT - Retention in care VMMC facility - Adherence to treatment

Universal treatment for HIV +ve irrespective of CD4 count

centre

**CHiPs: Community HIV-care Providers** PMTCT: Prevention of Mother to Child

Transmission


VMMC: Voluntary Medical Male

Circumcision

TB: Tuberculosis

STI: Sexually Transmitted Infections


#### Intervention arm















### **Knowledge of HIV status**

	Standard of Care % (n/N)	HIV-ST % (n/N)	Adjusted OR (95% CI)	P-value
Overall	65.3 (8,952/13,706)	68.0 (9,027/13,267)	1.30 (1.03, 1.65)	0.03
Males	55.1 (3,571/6,486)	60.4 (3,843/6,368)	1.31 (1.07, 1.60)	0.009
Females	74.5 (5,381/7,220)	75.1 (5,184/6,899)	1.05 (0.86, 1.30)	0.62
Young adults (16-29)	70.2 (4,917/7,002)	73.5 (4,972/6,769)	1.31 (1.05, 1.63)	0.02
Older adults (30+)	60.2 (4,035/6,704)	62.4 (4,055/6,498)	1.22 (0.98, 1.52)	0.07
Resident in R1 and R2, and not previously tested in R1 or R2	20.6 (117/567)	29.7 (173/583)	1.76 (1.25,2.48)	0.001





#### Qualitative Findings (40 IDI & 11 FGD, 91 participants)



#### **Acceptable for:**





- Previously tested HIV-negative
- Busy and mobile people
- Married men
- Living with partner
- Key Population e.g. sex worker
- Higher social class
- Formally employed

- Reduced clinic based barriers to HTS i.e. stigma, congestion
- Enhanced confidentiality
- Convenience and control
- Empowerment from knowing how to test





### Summary of key findings

- HIVST increased knowledge of HIV status among:
  - General population of adults aged ≥16 years
  - Men
  - Younger adults (aged 16 to 29)
  - Those previously NOT tested in round 1 and 2 of intervention.
- HIVST was acceptable and safe
  - Few social harms were reported
  - No self harm
- Secondary distribution was feasible and led to increased couple testing





### Implications of findings

- We have extended the offer of HIV-ST to all Zambia PopART intervention sites for
  - Those who refuse standard testing
  - Absent household members (adults only)
- Zambia has adopted HIV-ST as part of its national policy
  - Costed roll out plan being developed
  - Global Fund request contained 100,000 HIV-ST for this year
  - PEPFAR also expanding HIV-ST





#### With thanks to:

- All research participants and their families
- The 4 research communities and their religious, traditional, secular and civil leadership structures
- Volunteers in the community advisory board structures

All of the CHiPs workers and field researchers





#### **ACKNOWLEDGEMENTS**

HPTN071 is Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements # UM1 Al068619, UM1-Al068613

- Funded by:
- The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
- The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation
- NIAID, the National Institute of Mental Health (NIMH), and the National Institute on Drug Abuse (NIDA) all part of the U.S. National Institutes of Health (NIH)

This ancillary study was funded by The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation and sponsored by Zambart.

HIV-ST kits were provided as part of the UNITAID- PSI Self Testing Africa (STAR) consortium

The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

#### **ACKNOWLEDGEMENTS**

- This sub-study was funded by The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation and sponsored by Zambart.
- HIV-ST kits were provided as part of the UNITAID- PSI Self Testing Africa (STAR) consortium
- HPTN071 is Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements # UM1 Al068619, UM1-Al068617, and UM1-Al068613
  - Funded by:
    - The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
    - The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation
    - NIAID, the National Institute of Mental Health (NIMH), and the National Institute on Drug Abuse (NIDA) all part
      of the U.S. National Institutes of Health (NIH)
- This sub-study was funded by The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation and sponsored by Zambart.
- HIV-ST kits were provided as part of the UNITAID- PSI Self Testing Africa (STAR) consortium

Conflicts of Interest: None to declare